Veraxa Biotech Holding AG (NASDAQ:VRXA) Sees Significant Drop in Short Interest

Veraxa Biotech Holding AG (NASDAQ:VRXA) was the target of a large decrease in short interest during the month of August. As of August 31st, there was short interest totaling 202,960 shares, a decrease of 46.3% from the August 15th total of 378,219 shares. Based on an average daily trading volume, of 204,024 shares, the short-interest ratio is presently 1.0 days. Approximately 0.6% of the shares of the company are short sold.

Veraxa Biotech Price Performance

Shares of NASDAQ:VRXA traded down $0.12 during trading on Tuesday, reaching $1.50. The stock had a trading volume of 33,983 shares, compared to its average volume of 558,830. Veraxa Biotech has a 52 week low of $1.27 and a 52 week high of $27.36.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded Veraxa Biotech from a “sell” rating to a “hold” rating in a research report on Monday, August 31st.

Insider Activity at Veraxa Biotech

In other news, Director Oliver Rolf Baumann acquired 50,000 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The shares were acquired at an average price of $1.50 per share, with a total value of $75,000.00. Following the acquisition, the director directly owned 5,773,618 shares in the company, valued at approximately $8,660,427. The trade was a 0.87% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

About Veraxa Biotech

Veraxa Biotech AG is a biotechnology company focused on developing targeted antibody-based medicines, with an emphasis on antibody-drug conjugates (ADCs). These therapies are designed to use antibodies to identify specific cells and deliver therapeutic agents more selectively.

The company’s work includes antibody discovery, therapeutic development and the design of ADC candidates that combine targeting antibodies with drug payloads. Its research is directed primarily toward potential treatments for cancer and other serious diseases, although specific development programs and product approvals may change as its pipeline advances.

Publicly available information about Veraxa Biotech’s corporate history, geographic operations and leadership is limited.